Skip to main content

FDA Updates

Gavreto Now Approved for Thyroid Cancer with RET Fusions

Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer

Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma

Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma

Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

Opdivo plus Yervoy and Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

12
13
14
15
16
17
18

Page 15 of 33
Results 141 - 150 of 330